EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 26 / No 6-7 (Juin–Juillet 2010) Med Sci (Paris), 26 6-7 (2010) 641-646 References
Free Access
Issue
Med Sci (Paris)
Volume 26, Number 6-7, Juin–Juillet 2010
Page(s) 641 - 646
Section M/S revues
DOI https://doi.org/10.1051/medsci/2010266-7641
Published online 15 June 2010
  1. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol ; 47 : 513-39. [Google Scholar]
  2. Weber WW. The molecular basis of hereditary acetylation polymorphisms. DrugMetab Dispos 1986 ; 14 : 377-81. [Google Scholar]
  3. Bourdi M, Larrey D, Nataf J, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990 ; 85 : 1967-73. [Google Scholar]
  4. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998 ; 11 : 969-88. [Google Scholar]
  5. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999 ; 5 : 1249-55. [Google Scholar]
  6. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002 ; 2 : 301-5. [Google Scholar]
  7. Demoly P, Hillaire-Buys D, Raison-Peyron N, et al. Identifier et comprendre les allergies médicamenteuses. Med sci (Paris) 2003; 19 : 327-36. [Google Scholar]
  8. Harrill AH, Rusyn I. Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin Drug Metab Toxicol 2008; 4 : 1379-89. [Google Scholar]
  9. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009 ; 113 : 784-92. [Google Scholar]
  10. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood ; 111 : 4106-12. [Google Scholar]
  11. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009 ; 5 : e1000433. [Google Scholar]
  12. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009 ; 10 : 261-6. [Google Scholar]
  13. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001 ; 23 : 1603-14. [Google Scholar]
  14. Hughes AR, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008 ; 8 : 365-74. [Google Scholar]
  15. Nelson MR, Bacanu SA, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009 ; 9 : 23-33. [Google Scholar]
  16. Hughes S, Hughes A, Brothers C, et al. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat 2008 ; 7 : 121-9. [Google Scholar]
  17. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008 ; 8 : 186-95. [Google Scholar]
  18. Thome-Kromer B, Bonk I, Klatt M, et al. Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics 2003 ; 3 : 1835-62. [Google Scholar]
  19. Bandara LR, Kelly MD, Lock EA, Kennedy S. A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol Sci 2003 ; 73 : 195-206. [Google Scholar]
  20. Séguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. Chem Res Toxicol 2005 ; 18 : 1 193-202. [Google Scholar]
  21. Lu W, Li X, Uetrecht JP. Changes in gene expression induced by carbamazepine and phenytoin: testing the danger hypothesis. J Immunotoxicol 2008 ; 5 : 107-13. [Google Scholar]
  22. Pacitto SR, Uetrecht JP, Boutros PC, Popovic M. Changes in gene expression induced by tienilic Acid and sulfamethoxazole: testing the danger hypothesis. J Immunotoxicol 2007 ; 4 : 253-66. [Google Scholar]
  23. Waring JF, Liguori MJ, Luyendyk JP, et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006 ; 316 : 1080-7. [Google Scholar]
  24. Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 2007 ; 100 : 259-66. [Google Scholar]
  25. Shaw PJ, Ditewig AC, Waring JF, et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci 2009 ; 107 : 270-80. [Google Scholar]
  26. Kier LD, Neft R, Tang L, et al. Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 2004 ; 549 : 101-13. [Google Scholar]
  27. Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009 ; 237 : 317-30. [Google Scholar]
  28. Luyendyk JP, Maddox JF, Cosma GN, et al. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003 ; 307 : 9-16. [Google Scholar]
  29. Le Bonniec B. La cible de la warfarine identifiée. Med Sci (Paris) 2004 ; 20 : 512-4. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.